Nuclear survivin expression: A prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer

Yao Kuang Wu, Chun Yao Huang, Mei Chen Yang, Chou Chin Lan, Chih Hsin Lee, Err Cheng Chan, Kuei Tien Chen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Survivin, a structurally unique protein expressed in most common human neoplasms, is thought to support cell cycle progression and suppress apoptosis. Survivin expression is highly correlated with advanced non-small cell lung cancer (NSCLC) and poor prognosis. In this retrospective study of banked pathology tissue of patients with advanced NSCLC, we tested for correlations of N-survivin expression in tumor tissues and responsiveness to treatment with platinum-based regimens containing paclitaxel or docetaxel. The 48 patients with NSCLC included 32 (66.7%) males and 16 (33.3%) females. Mean age at diagnosis was 59.4 years (range 36-83 years), and median follow-up time was 20.4 months (range 3.4-59.0 months). Patients with high tumor N-survivin expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P <0.001). Adjusted multivariate modeling found high tumor N-survivin expression to be an independent prognostic factor for a clinical response to chemotherapy (high vs. low, OR 6.14, 95% CI 1.62-23.29; P = 0.008). Median overall survival differed significantly between those with high tumor N-survivin expression who did/did not respond to chemotherapy and between those with low tumor N-survivin expression who did/did not respond to chemotherapy (P <0.05). Tumor N-survivin expression shows promise as a predictive biomarker in the chemotherapy setting as a surrogate marker of high proliferation status.

Original languageEnglish
Article number79
JournalMedical Oncology
Volume31
Issue number8
DOIs
Publication statusPublished - 2014
Externally publishedYes

Keywords

  • Docetaxel
  • Non-small cell lung cancer
  • Paclitaxel
  • Platinum-taxane chemotherapy
  • Survivin expression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Nuclear survivin expression: A prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this